By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Ponatinib (systemic) (monograph)
Drugs

Ponatinib (systemic) (monograph)

https://themeditary.com/drug/ponatinib-systemic-monograph-22867.html
Medically Reviewed by Glamora Samuels, MD TheMediTary.Com | Reviewed: Oct 12, 2023  Additional Content by TheMediTary.Com

Generic name: iclusig

Availability: Prescription only

Pregnancy & Lactation: Risk data available

Brand names: Iclusig, Ponatinib

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

What is Ponatinib (systemic) (monograph)?

Warning

    Arterial Occlusive Events
  • Arterial occlusive and thromboembolic events, including fatal MI, stroke, stenosis of large arterial vessels of the brain, severe peripheral vascular disease, and requirement for urgent revascularization procedures, occurred in patients receiving ponatinib.

  • Arterial occlusive events observed in patients with or without cardiovascular risk factors, including patients ≤50 years of age.

  • If an arterial occlusive event occurs, interrupt or discontinue ponatinib based on severity. Consider whether the benefits of restarting ponatinib therapy outweighs the risks.

    Venous Thromboembolic Events
  • Venous thromboembolic events occurred in patients receiving ponatinib. Monitor for evidence of venous thromboembolic events.

  • If a venous thromboembolic event occurs, interrupt or discontinue ponatinib based on severity.

    Heart Failure
  • Serious or fatal heart failure observed.

  • Monitor for heart failure and manage as clinically indicated.

  • If new or worsening heart failure occurs, interrupt therapy or discontinue ponatinib.

    Hepatotoxicity
  • Hepatotoxicity, liver failure, and death observed.

  • Monitor liver function tests prior to initiation of therapy and at least monthly thereafter or as clinically indicated.

  • If hepatotoxicity occurs, interrupt therapy and reduce dosage upon resumption, or discontinue ponatinib.

Introduction

Antineoplastic agent; an inhibitor of multiple receptor tyrosine kinases.

Uses for PONATinib (Systemic)

Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphocytic (Lymphoblastic) Leukemia (ALL) Following Treatment Failure

Treatment of T315I BCR-ABL mutation-positive chronic phase, accelerated phase, or blast phase CML and of T315I BCR-ABL mutation-positive Philadelphia chromosome-positive (Ph+) ALL in adults.

Treatment of accelerated phase CML, blast phase CML, or Ph+ ALL in adults in whom no other tyrosine kinase inhibitor (TKI) therapy may be used; designated an orphan drug by FDA for these uses.

Treatment of chronic phase CML with resistance or intolerance to ≥2 prior kinase inhibitors in adults.

Not recommended for treatment of newly diagnosed chronic phase CML.

According to some experts, ponatinib is the agent of choice in patients with CML and the T315I mutation, and in instances where other TKIs are not indicated. Important factors to consider when deciding to initiate ponatinib treatment in CML include disease state, mutational status, line of treatment, reason for change of therapy (resistance or intolerance), and specific comorbidities. Patients with T315I BCR-ABL mutation-positive Ph+ ALL may respond to ponatinib therapy.

PONATinib (Systemic) Dosage and Administration

General

Pretreatment Screening

  • Verify pregnancy status of females of reproductive potential prior to initiating ponatinib.

  • Perform liver function tests at baseline.

  • Measure blood pressure at baseline.

  • Conduct a comprehensive eye exam at baseline.

  • Ensure adequate hydration and treat high uric acid levels prior to initiating ponatinib.

Patient Monitoring

  • Monitor liver function tests at least monthly or as clinically indicated.

  • Monitor serum lipase every 2 weeks for the first 2 months, then monthly thereafter or as clinically indicated; consider additional serum lipase monitoring in patients with a history of pancreatitis or alcohol abuse.

  • Monitor CBC every 2 weeks for the first 3 months, then monthly or as clinically indicated.

  • Monitor blood pressure as clinically indicated.

  • Monitor for evidence of arterial occlusive events and venous thromboembolism.

  • Monitor for signs or symptoms of heart failure.

  • Monitor for signs and symptoms suggestive of slow heart rate (e.g., fainting, dizziness) or rapid heart rate (e.g., chest pain, palpitations, dizziness).

  • Monitor for symptoms of neuropathy (e.g., hypoesthesia, hyperesthesia, paresthesia, discomfort, burning sensation, neuropathic pain or weakness).

  • Conduct comprehensive eye exams periodically during treatment.

  • Monitor for the presence of fluid retention and hemorrhage.

Dispensing and Administration Precautions

  • To avoid medication errors, the Institute for Safe Medication Practices (ISMP) recommends that prescribers communicate both the brand and generic names for ponatinib on the prescription order form.

  • Based on ISMP, ponatinib is a high-alert medication that has a heightened risk of causing significant patient harm when used in error.

Administration

Oral Administration

Administer orally once daily without regard to meals.

Swallow tablets whole; do not crush, break, cut, or chew tablets.

If a dose is missed, give next dose at the regularly scheduled time the next day.

Dosage

Available as ponatinib hydrochloride; dosage expressed in terms of ponatinib.

Adults

Chronic Phase CML
Oral

Initially, 45 mg once daily; reduce to 15 mg once daily upon achievement of BCR-ABL1 IS ≤1%.

  • Re-escalate dosage to a previously tolerated dosage of 30 or 45 mg once daily if response is lost on 15 mg once daily.

  • Continue until loss of response at re-escalated dosage or unacceptable toxicity.

  • Consider discontinuation if hematologic response not achieved by 3 months.

Accelerated Phase or Blast Phase CML or Ph+ ALL
Oral

Initially, 45 mg once daily; optimal dosage not established.

  • Consider dosage reduction in patients with accelerated phase CML who have achieved major cytogenetic response.

  • Continue until loss of response or unacceptable toxicity.

  • Consider discontinuation if hematologic response not achieved by 3 months.

Dosage Modification for Toxicity

If adverse reactions occur, temporary interruption of therapy, dosage reduction, and/or discontinuance of ponatinib may be necessary. If dosage modification required, reduce dosage as described in Table 1. Permanently discontinue in patients who are unable to tolerate the lowest dosage described in Table 1.

Table 1. Recommended Dosage Reduction for Ponatinib Toxicity.1

Dosage Reduction

Chronic Phase CML

Accelerated Phase or Blast Phase CML, or Ph+ ALL

First

30 mg once daily

30 mg once daily

Second

15 mg once daily

15 mg once daily

Third

10 mg once daily

Permanently discontinue if patient is unable to tolerate 15 mg once daily

Fourth and subsequent reductions

Permanently discontinue if patient is unable to tolerate 10 mg once daily

Not applicable

If an adverse reaction occurs, reduce ponatinib dosage, or interrupt or permanently discontinue therapy as described in Table 2.

Table 2. Recommended Dosage Modification for Ponatinib Toxicity.1

Adverse Reaction and Severity

Modification

Cardiovascular or Cerebrovascular Arterial Occlusive Event

Grade 1

Withhold ponatinib until resolved, then resume at the same dosage

Grade 2

Withhold ponatinib until grade 0 or 1, then resume at the next lower dosage; discontinue ponatinib if event recurs

Grade 3 or 4

Discontinue ponatinib

Peripheral Vascular or Other Arterial Occlusive Event

Grade 1

Withhold ponatinib until resolved, then resume at the same dosage

Grade 2

Withhold ponatinib until grade 0 or 1, then resume at the same dosage; if event recurs, withhold ponatinib until grade 0 or 1, then resume at the next lower dosage

Grade 3

Withhold ponatinib until grade 0 or 1, then resume at the next lower dosage; discontinue ponatinib if event recurs

Grade 4

Discontinue ponatinib

Venous Thromboembolism

Grade 1

Withhold ponatinib until resolved, then resume at the same dosage

Grade 2

Withhold ponatinib until grade 0 or 1, then resume at the same dosage; if event recurs, withhold ponatinib until grade 0 or 1, then resume at the next lower dosage

Grade 3

Withhold ponatinib until grade 0 or 1, then resume at the next lower dosage; discontinue ponatinib if event recurs

Grade 4

Discontinue ponatinib

Heart Failure

Grade 2 or 3

Withhold ponatinib until grade 0 or 1, then resume at the next lower dosage; discontinue ponatinib if event recurs

Grade 4

Discontinue ponatinib

Hepatotoxicity

AST or ALT >3 times ULN

Withhold ponatinib until grade 0 or 1, then resume at the next lower dosage

AST or ALT ≥3 times ULN concurrent with bilirubin >2 times ULN and alkaline phosphatase <2 times ULN

Discontinue ponatinib

Pancreatitis or Elevated Serum Lipase

Serum lipase >1 to 1.5 times ULN

Consider withholding ponatinib until resolution, then resume at same dosage

Serum lipase >1.5 to 2 times ULN, serum lipase 2 to 5 times ULN and asymptomatic, or asymptomatic radiologic pancreatitis

Withhold ponatinib until grade 0 or 1 (<1.5 times ULN), then resume at next lower dosage

Serum lipase >2 to 5 times ULN and symptomatic, symptomatic grade 3 pancreatitis, or serum lipase >5 times ULN and asymptomatic

Withhold ponatinib until complete resolution of symptoms and after recovery of lipase elevation to grade 0 or 1; then resume at the next lower dosage

Symptomatic pancreatitis and serum lipase >5 times ULN

Discontinue ponatinib

Myelosuppression

ANC <1000/mm3 or platelets <50,000/mm3

Withhold ponatinib until ANC ≥1500/mm3 and platelets ≥75,000/mm3, then resume at the same dosage; if myelosuppression recurs, withhold ponatinib until resolution, then resume at the next lower dosage

Other Non-Hematologic Adverse Events

Grade 1

Withhold ponatinib until resolved, then resume at the same dosage

Grade 2

Withhold ponatinib until grade 0 or 1, then resume at the same dosage; if event recurs, withhold ponatinib until grade 0 or 1, then resume at the next lower dosage

Grade 3 or 4

Withhold ponatinib until grade 0 or 1, then resume at the next lower dosage; if event recurs, discontinue ponatinib

Dosage Modification for Concomitant Use with Potent CYP3A Inhibitors

Avoid concomitant use of ponatinib with potent CYP3A inhibitors when possible. If concomitant use cannot be avoided, reduce ponatinib dosage as described in Table 3. After discontinuing a potent CYP3A inhibitor for 3–5 elimination half-lives, resume the dosage of ponatinib that was tolerated prior to initiating the potent CYP3A inhibitor.

Table 3. Recommended Dosage for Ponatinib Coadministered with Potent CYP3A Inhibitors.1

Current Ponatinib Dosage

Recommended Ponatinib Dosage with a Potent CYP3A Inhibitor

45 mg once daily

30 mg once daily

30 mg once daily

15 mg once daily

15 mg once daily

10 mg once daily

10 mg once daily

Avoid coadministration of ponatinib with a potent CYP3A inhibitor

Special Populations

Hepatic Impairment

Hepatic impairment (Child-Pugh class A, B, or C): reduce initial dosage from 45 mg once daily to 30 mg once daily.

Renal Impairment

No specific dosage recommendations at this time.

Geriatric Use

Select dosage with caution because of greater frequency of age-related decreases in hepatic, renal, and/or cardiac function and of concomitant disease and drug therapy.

Detailed Ponatinib dosage information

Warnings

Contraindications

  • None.

Warnings/Precautions

Warnings

Arterial Occlusive Events

Arterial occlusive events, including fatalities, have occurred in patients receiving ponatinib in clinical trials.

Consider whether benefits of ponatinib therapy outweigh risks. Monitor patients for manifestations of arterial occlusive events. If arterial occlusion is suspected, interrupt or discontinue therapy. Following evaluation, weigh the risks and benefits of restarting ponatinib.

Venous Thromboembolic Events

Serious or severe venous thromboembolic events have occurred in patients receiving ponatinib.

Monitor patients for manifestations of venous thromboembolic events. If a venous thromboembolic event occurs, interrupt treatment, then resume at the same or a decreased dose or discontinue ponatinib based on recurrence/severity.

Heart Failure

Serious or severe heart failure events, including fatalities, have occurred.

Monitor for manifestations of heart failure; manage as clinically indicated.

If new or worsening heart failure occurs, interrupt therapy and reduce dosage upon resumption or discontinue ponatinib.

Hepatotoxicity

Risk of hepatotoxicity, including liver failure and death. Fulminant hepatic failure resulting in death following 1 week of therapy has occurred rarely. Liver enzyme elevations occur commonly.

Fatalities occurred in patients with blast phase CML or Ph+ ALL.

Perform liver function tests prior to initiation of therapy and at least monthly thereafter or as clinically indicated.

If hepatotoxicity occurs, interrupt therapy and reduce dosage, or discontinue ponatinib.

Other Warnings and Precautions

Hypertension

Serious or severe hypertension, including hypertensive crisis, observed. Blood pressure elevations occur commonly. Urgent clinical intervention for symptoms associated with hypertension (e.g., confusion, headache, chest pain, shortness of breath) may be required.

Monitor BP and treat as clinically indicated. If hypertension is not medically controlled, interrupt therapy, reduce the dosage, or discontinue ponatinib. For significant worsening, labile, or treatment-resistant hypertension, interrupt ponatinib and consider evaluation for renal artery stenosis.

Pancreatitis

Pancreatitis and pancreatic laboratory abnormalities (e.g., elevated serum amylase and lipase) observed. Most cases resolve within 2 weeks of interruption of therapy or dosage reduction.

Monitor serum lipase concentrations every 2 weeks during the first 2 months of therapy and then monthly thereafter or as clinically indicated; consider more frequent monitoring in patients with a history of pancreatitis or alcohol abuse. If serum lipase concentrations are elevated and accompanied by abdominal pain, evaluate the patient for pancreatitis.

If pancreatitis occurs, interrupt therapy, then resume at the same or a reduced dosage, or discontinue ponatinib.

Increased Toxicity in Newly Diagnosed Chronic Phase CML

Ponatinib not indicated or recommended for use in patients with newly diagnosed chronic phase CML. Arterial and venous thrombosis and occlusions occurred at least twice as often in patients receiving ponatinib compared to patients receiving imatinib. Patients receiving ponatinib also had a higher incidence of myelosuppression, pancreatitis, hepatotoxicity, cardiac failure, hypertension, and skin and subcutaneous tissue disorders.

Neuropathy

Peripheral and cranial neuropathy observed; onset has occurred during the initial month of therapy. Most common peripheral neuropathies were paresthesia, hypoesthesia, and muscular weakness.

Monitor patient for manifestations of neuropathy.

If neuropathy occurs, interrupt therapy, then resume at the same or a reduced dosage, or discontinue ponatinib.

Ocular Toxicity

Serious ocular toxicities leading to blindness or blurred vision observed. Retinal toxicities (i.e., macular edema, age-related macular degeneration, retinal vein occlusion, retinal hemorrhage, vitreous floaters), blurred vision, eye pain, and dry eye have occurred.

Perform comprehensive ophthalmologic examination at baseline and periodically during therapy.

Hemorrhage

Hemorrhage, sometimes serious or fatal, observed; increased incidence of serious hemorrhage in patients with accelerated or blast phase CML or Ph+ ALL than in patients with chronic phase CML. Most serious hemorrhagic events were GI hemorrhage or subdural hematoma. Hemorrhagic events occurred principally in patients with grade 4 thrombocytopenia.

Monitor for hemorrhage and manage as clinically indicated. If hemorrhage occurs, interrupt therapy, then resume at the same or a reduced dosage, or discontinue ponatinib.

Fluid Retention

Risk of serious fluid retention (i.e., pleural effusion, pericardial effusion, angioedema); brain edema resulting in death reported rarely.

Monitor for signs and symptoms of fluid retention. If fluid retention develops, manage patients as clinically indicated and interrupt therapy, then resume at the same or a reduced dosage, or discontinue ponatinib.

Cardiac Arrhythmias

Grade 3 or 4 cardiac arrhythmia events, sometimes requiring hospitalization, reported, including atrial fibrillation, atrial flutter, ventricular arrhythmia, symptomatic bradyarrhythmia requiring pacemaker implantation, cardiorespiratory arrest, supraventricular extrasystoles, supraventricular and ventricular tachycardia, atrial tachycardia, sinus bradycardia, bradycardia, QT prolongation, complete atrioventricular block, sinus node dysfunction, loss of consciousness, and syncope.

Monitor for signs and symptoms of slow heart rate (e.g., fainting, dizziness) or rapid heart rate (e.g., chest pain, palpitations, dizziness) and manage as clinically indicated. If cardiac arrhythmias occur, interrupt therapy, then resume at the same or a reduced dosage, or discontinue ponatinib.

Myelosuppression

Risk of grade 3 or 4 myelosuppression (i.e., neutropenia, anemia, thrombocytopenia); incidence increased in patients with blast or accelerated phase CML or Ph+ ALL.

Monitor CBCs every 2 weeks during the first 3 months of therapy and then monthly (or as clinically indicated) thereafter. If hematologic toxicity occurs, interrupt therapy, then resume at the same or a reduced dosage.

Tumor Lysis Syndrome

Tumor lysis syndrome and hyperuricemia reported.

Ensure adequate hydration and treat hyperuricemia prior to initiation of ponatinib.

Reversible Posterior Leukoencephalopathy Syndrome

Reversible posterior leukoencephalopathy syndrome (RPLS) reported. Symptoms include hypertension, seizure, headache, decreased alertness, altered mental function, vision loss, and other visual and neurological disturbances. Magnetic resonance imaging is necessary to confirm diagnosis.

If RPLS occurs, interrupt ponatinib until resolution; safety of resuming ponatinib upon resolution is unknown.

Wound Healing Complications and GI Perforation

Impaired wound healing reported. Withhold ponatinib for ≥1 week before elective surgery and do not administer following major surgery for ≥2 weeks and until adequate wound healing occurs. Safety of ponatinib resumption after resolution of wound healing complications not established.

Gastrointestinal perforation or fistula reported. Permanently discontinue ponatinib in patients with GI perforation.

Fetal/Neonatal Morbidity and Mortality

May cause fetal harm based on mechanism of action and findings from animal studies. Verify pregnancy status of females of reproductive potential prior to initiating therapy. Advise females of reproductive potential to use effective contraception during therapy and for 3 weeks after the last dose. If used during pregnancy or if patient becomes pregnant, apprise patient of potential fetal hazard.

Specific Populations

Pregnancy

May cause fetal harm based on mechanism of action and findings from animal studies. No data available in human pregnancy. Verify pregnancy status of females of reproductive potential prior to initiating therapy. If used during pregnancy or if patient becomes pregnant, apprise patient of potential fetal hazard.

Lactation

No data on the presence of ponatinib in human milk or effects on the breastfed child or on milk production. Advise patients to avoid breastfeeding during ponatinib treatment and for 6 days following the last dose.

Females and Males of Reproductive Potential

Based on its mechanism of action and findings from animal studies, ponatinib may cause fetal harm. Verify the pregnancy status of females of reproductive potential prior to initiating therapy. Advise females of reproductive potential to use effective contraception during therapy and for 3 weeks after the last dose.

May impair fertility in females of reproductive potential; not known whether these effects on fertility are reversible.

Pediatric Use

Safety and efficacy not established.

Geriatric Use

In the OPTIC trial in patients with chronic phase CML, patients ≥65 years of age had lower rates of BCR-ABL1 IS ≤1% at 12 months compared to younger patients (27% versus 47%). Patients ≥65 years of age were also more likely to experience arterial occlusive events compared to younger patients (38% versus 9%).

In the PACE trial, the major cytogenetic response rate in patients with chronic phase CML was 40% in patients ≥65 years of age compared with 65% in patients <65 years of age. In patients with accelerated or blast phase CML or Ph+ ALL, the major hematologic response rate was 45% in patients ≥65 years of age compared with 44% in patients <65 years of age. Arterial occlusive events occurred in 35% of patients ≥65 years of age and 21% of patients <65 years of age.

Certain toxicities may occur more frequently in geriatric patients ≥65 years of age. Select dosage cautiously in geriatric patients.

Hepatic Impairment

Hepatic impairment (Child-Pugh class A, B, or C) did not increase pharmacokinetic exposure to ponatinib, but patients with hepatic impairment are more likely to experience adverse reactions. Reduce initial dosage of ponatinib in patients with pre-existing hepatic impairment.

Renal Impairment

No clinically significant difference in pharmacokinetics observed in patients with mild to moderate renal impairment (Clcr 30–89 mL/min). Data lacking in patients with severe renal impairment.

Common Adverse Effects

Most common adverse reactions (>20%) include rash and related conditions, arthralgia, abdominal pain, headache, constipation, dry skin, hypertension, fatigue, fluid retention and edema, pyrexia, nausea, pancreatitis/lipase elevation, hemorrhage, anemia, hepatic dysfunction, arterial occlusive events.

Grade 3 or 4 laboratory abnormalities (>20%) include decreased platelet count, decreased neutrophil count, decreased white blood cell count.

How should I use Ponatinib (systemic) (monograph)

General

Pretreatment Screening

  • Verify pregnancy status of females of reproductive potential prior to initiating ponatinib.

  • Perform liver function tests at baseline.

  • Measure blood pressure at baseline.

  • Conduct a comprehensive eye exam at baseline.

  • Ensure adequate hydration and treat high uric acid levels prior to initiating ponatinib.

Patient Monitoring

  • Monitor liver function tests at least monthly or as clinically indicated.

  • Monitor serum lipase every 2 weeks for the first 2 months, then monthly thereafter or as clinically indicated; consider additional serum lipase monitoring in patients with a history of pancreatitis or alcohol abuse.

  • Monitor CBC every 2 weeks for the first 3 months, then monthly or as clinically indicated.

  • Monitor blood pressure as clinically indicated.

  • Monitor for evidence of arterial occlusive events and venous thromboembolism.

  • Monitor for signs or symptoms of heart failure.

  • Monitor for signs and symptoms suggestive of slow heart rate (e.g., fainting, dizziness) or rapid heart rate (e.g., chest pain, palpitations, dizziness).

  • Monitor for symptoms of neuropathy (e.g., hypoesthesia, hyperesthesia, paresthesia, discomfort, burning sensation, neuropathic pain or weakness).

  • Conduct comprehensive eye exams periodically during treatment.

  • Monitor for the presence of fluid retention and hemorrhage.

Dispensing and Administration Precautions

  • To avoid medication errors, the Institute for Safe Medication Practices (ISMP) recommends that prescribers communicate both the brand and generic names for ponatinib on the prescription order form.

  • Based on ISMP, ponatinib is a high-alert medication that has a heightened risk of causing significant patient harm when used in error.

Administration

Oral Administration

Administer orally once daily without regard to meals.

Swallow tablets whole; do not crush, break, cut, or chew tablets.

If a dose is missed, give next dose at the regularly scheduled time the next day.

Dosage

Available as ponatinib hydrochloride; dosage expressed in terms of ponatinib.

Adults

Chronic Phase CML
Oral

Initially, 45 mg once daily; reduce to 15 mg once daily upon achievement of BCR-ABL1 IS ≤1%.

  • Re-escalate dosage to a previously tolerated dosage of 30 or 45 mg once daily if response is lost on 15 mg once daily.

  • Continue until loss of response at re-escalated dosage or unacceptable toxicity.

  • Consider discontinuation if hematologic response not achieved by 3 months.

Accelerated Phase or Blast Phase CML or Ph+ ALL
Oral

Initially, 45 mg once daily; optimal dosage not established.

  • Consider dosage reduction in patients with accelerated phase CML who have achieved major cytogenetic response.

  • Continue until loss of response or unacceptable toxicity.

  • Consider discontinuation if hematologic response not achieved by 3 months.

Dosage Modification for Toxicity

If adverse reactions occur, temporary interruption of therapy, dosage reduction, and/or discontinuance of ponatinib may be necessary. If dosage modification required, reduce dosage as described in Table 1. Permanently discontinue in patients who are unable to tolerate the lowest dosage described in Table 1.

Table 1. Recommended Dosage Reduction for Ponatinib Toxicity.1

Dosage Reduction

Chronic Phase CML

Accelerated Phase or Blast Phase CML, or Ph+ ALL

First

30 mg once daily

30 mg once daily

Second

15 mg once daily

15 mg once daily

Third

10 mg once daily

Permanently discontinue if patient is unable to tolerate 15 mg once daily

Fourth and subsequent reductions

Permanently discontinue if patient is unable to tolerate 10 mg once daily

Not applicable

If an adverse reaction occurs, reduce ponatinib dosage, or interrupt or permanently discontinue therapy as described in Table 2.

Table 2. Recommended Dosage Modification for Ponatinib Toxicity.1

Adverse Reaction and Severity

Modification

Cardiovascular or Cerebrovascular Arterial Occlusive Event

Grade 1

Withhold ponatinib until resolved, then resume at the same dosage

Grade 2

Withhold ponatinib until grade 0 or 1, then resume at the next lower dosage; discontinue ponatinib if event recurs

Grade 3 or 4

Discontinue ponatinib

Peripheral Vascular or Other Arterial Occlusive Event

Grade 1

Withhold ponatinib until resolved, then resume at the same dosage

Grade 2

Withhold ponatinib until grade 0 or 1, then resume at the same dosage; if event recurs, withhold ponatinib until grade 0 or 1, then resume at the next lower dosage

Grade 3

Withhold ponatinib until grade 0 or 1, then resume at the next lower dosage; discontinue ponatinib if event recurs

Grade 4

Discontinue ponatinib

Venous Thromboembolism

Grade 1

Withhold ponatinib until resolved, then resume at the same dosage

Grade 2

Withhold ponatinib until grade 0 or 1, then resume at the same dosage; if event recurs, withhold ponatinib until grade 0 or 1, then resume at the next lower dosage

Grade 3

Withhold ponatinib until grade 0 or 1, then resume at the next lower dosage; discontinue ponatinib if event recurs

Grade 4

Discontinue ponatinib

Heart Failure

Grade 2 or 3

Withhold ponatinib until grade 0 or 1, then resume at the next lower dosage; discontinue ponatinib if event recurs

Grade 4

Discontinue ponatinib

Hepatotoxicity

AST or ALT >3 times ULN

Withhold ponatinib until grade 0 or 1, then resume at the next lower dosage

AST or ALT ≥3 times ULN concurrent with bilirubin >2 times ULN and alkaline phosphatase <2 times ULN

Discontinue ponatinib

Pancreatitis or Elevated Serum Lipase

Serum lipase >1 to 1.5 times ULN

Consider withholding ponatinib until resolution, then resume at same dosage

Serum lipase >1.5 to 2 times ULN, serum lipase 2 to 5 times ULN and asymptomatic, or asymptomatic radiologic pancreatitis

Withhold ponatinib until grade 0 or 1 (<1.5 times ULN), then resume at next lower dosage

Serum lipase >2 to 5 times ULN and symptomatic, symptomatic grade 3 pancreatitis, or serum lipase >5 times ULN and asymptomatic

Withhold ponatinib until complete resolution of symptoms and after recovery of lipase elevation to grade 0 or 1; then resume at the next lower dosage

Symptomatic pancreatitis and serum lipase >5 times ULN

Discontinue ponatinib

Myelosuppression

ANC <1000/mm3 or platelets <50,000/mm3

Withhold ponatinib until ANC ≥1500/mm3 and platelets ≥75,000/mm3, then resume at the same dosage; if myelosuppression recurs, withhold ponatinib until resolution, then resume at the next lower dosage

Other Non-Hematologic Adverse Events

Grade 1

Withhold ponatinib until resolved, then resume at the same dosage

Grade 2

Withhold ponatinib until grade 0 or 1, then resume at the same dosage; if event recurs, withhold ponatinib until grade 0 or 1, then resume at the next lower dosage

Grade 3 or 4

Withhold ponatinib until grade 0 or 1, then resume at the next lower dosage; if event recurs, discontinue ponatinib

Dosage Modification for Concomitant Use with Potent CYP3A Inhibitors

Avoid concomitant use of ponatinib with potent CYP3A inhibitors when possible. If concomitant use cannot be avoided, reduce ponatinib dosage as described in Table 3. After discontinuing a potent CYP3A inhibitor for 3–5 elimination half-lives, resume the dosage of ponatinib that was tolerated prior to initiating the potent CYP3A inhibitor.

Table 3. Recommended Dosage for Ponatinib Coadministered with Potent CYP3A Inhibitors.1

Current Ponatinib Dosage

Recommended Ponatinib Dosage with a Potent CYP3A Inhibitor

45 mg once daily

30 mg once daily

30 mg once daily

15 mg once daily

15 mg once daily

10 mg once daily

10 mg once daily

Avoid coadministration of ponatinib with a potent CYP3A inhibitor

Special Populations

Hepatic Impairment

Hepatic impairment (Child-Pugh class A, B, or C): reduce initial dosage from 45 mg once daily to 30 mg once daily.

Renal Impairment

No specific dosage recommendations at this time.

Geriatric Use

Select dosage with caution because of greater frequency of age-related decreases in hepatic, renal, and/or cardiac function and of concomitant disease and drug therapy.

Detailed Ponatinib dosage information
Ponatinib (systemic) (monograph) Dosage information (more detail)

What other drugs will affect Ponatinib (systemic) (monograph)?

Principally metabolized by CYP3A4 and, to a lesser extent, by CYP isoenzymes 2C8, 2D6, and 3A5.

Does not inhibit metabolism of substrates for CYP isoenzymes 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A; does not induce metabolism of substrates for CYP1A2, 2B6, or 3A.

Inhibits P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and bile salt export pump (BSEP); is a weak substrate for P-gp and BCRP.

Not a substrate for organic anion transport polypeptide (OATP) 1B1 or OATP1B3, or organic cation transporter (OCT) 1; does not inhibit OATP1B1, OATP1B3, OCT1, OCT2, organic anion transporter (OAT) 1, or OAT3.

Drugs and Foods Affecting Hepatic Microsomal Enzymes

Potent CYP3A inhibitors: Possible pharmacokinetic interaction (increased plasma concentrations of ponatinib). Avoid concomitant use when possible; if used concomitantly, reduce dosage of ponatinib.

Potent CYP3A inducers: Possible pharmacokinetic interaction (decreased plasma concentrations of ponatinib). Manufacturer recommends selecting medications with no or minimal CYP3A induction potential. Avoid concomitant use with potent CYP3A inducers unless potential benefit outweighs possible risk of reduced ponatinib exposure. Monitor for signs of reduced ponatinib efficacy if concomitant use cannot be avoided.

Specific Drugs and Food

Drug or Food

Interaction

Comments

Grapefruit juice

Possible increased serum concentrations of ponatinib

Do not consume grapefruit products concomitantly with ponatinib

Ketoconazole

Increased ponatinib peak concentration by 47% and AUC by 78%

Avoid concomitant use when possible; if used concomitantly, reduce ponatinib dosage

Lansoprazole

Decreased ponatinib peak concentration by 25% and AUC by 6%

Rifampin

Decreased ponatinib peak concentration by 42% and AUC by 62%

Avoid concomitant use unless potential benefit outweighs the potential risk of decreased ponatinib exposure; if concomitant use cannot be avoided, monitor for signs of reduced ponatinib efficacy

More about Ponatinib (systemic) (monograph) (Iclusig)

Dosage information
Ponatinib (systemic) (monograph) Side Effects
During pregnancy
Drug images
Side effects
Breastfeeding Warnings
Drug class: Drugs

Related treatment guides

Acute Lymphoblastic Leukemia
Chronic Myelogenous Leukemia
Share this Article
Contents
Uses Warnings Before Taking Dosage Side effects Interactions
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by